November 5, 2025

Consolidated Financial Results
for the First Six Months of the Fiscal Year Ending March 31, 2026
(Under Japanese GAAP)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: Tokyo Stock Exchange)
Code Number: 4559 (URL: https://www.zeria.co.jp/english/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Koichi Tamura, Director, Public Relations Division TEL (03) 3661-1039
Scheduled date to submit the Semi-annual Securities Report: November 7, 2025
Scheduled date to commence dividend payments: December 1, 2025
Preparation of supplementary documents to the financial results: Yes
Holding of financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2025 through September 30, 2025)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2025	39,960	(5.8)	3,641	(43.6)	2,656	(66.6)	1,737	(71.3)
September 30, 2024	42,422	15.7	6,459	21.2	7,949	44.6	6,061	12.3

Note: Comprehensive income: For the six months ended September 30, 2025: 3,073 million yen [(68.3)%]
For the six months ended September 30, 2024: 9,709 million yen [(13.7)%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2025	39.42	–
September 30, 2024	137.51	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
September 30, 2025	158,736	91,809	57.8
March 31, 2025	159,171	89,797	56.3

Reference: Equity: As of September 30, 2025: 91,671 million yen As of March 31, 2025: 89,539 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2025	–	23.00	–	24.00	47.00
Year ending March 31, 2026	–	24.00			
Year ending March 31, 2026 (Forecast)			–	24.00	48.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026 (April 1, 2025 through March 31, 2026)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	90,000	3.1	12,000	(1.6)	12,000	(6.5)	9,500	(4.4)	215.52

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: Yes

Inclusion: – (Company name: –) Exclusion: 1 Company (Kenso-Seiyaku Co., Ltd.)

Note: For details, please refer to “2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to semi-annual consolidated financial statements (Notes on significant changes in the scope of consolidation during the period)” on page 9 of the Attached Material.

(2) Application of special accounting for preparing the semi-annual consolidated financial statements: Yes

Note: For details, please refer to “2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to semi-annual consolidated financial statements (Notes on special accounting methods for preparation of semi-annual consolidated financial statements)” on page 9 of the Attached Material.

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):
As of September 30, 2025: 52,119,190 shares As of March 31, 2025: 53,119,190 shares
2) Number of shares of treasury shares as of the end of the term:
As of September 30, 2025: 8,039,707 shares As of March 31, 2025: 9,039,667 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the six months ended September 30, 2025: 44,079,485 shares
For the six months ended September 30, 2024: 44,079,667 shares

Note: Based on the resolution at a meeting of the Board of Directors held on August 5, 2025, the Company cancelled 1,000,000 treasury shares as of August 27, 2025.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors. For the assumptions made in financial forecasts and cautions concerning the use thereof, please refer to “1. Summary of Business Results (3) Explanation of consolidated financial forecasts and other forward-looking statements” on page 3 of the Attached Material.

○Table of contents of attachments

1. Summary of Business Results

(1) Summary of business results for the semi-annual period under review

Net sales for the first six months of the fiscal year ending March 31, 2026 were 39,960 million yen (down 5.8% from the same period of the previous fiscal year). Operating profit was 3,641 million yen (down 43.6% from the same period of the previous fiscal year) due to a decrease in sales and increased expenses such as cost and expenses related to core system investments in overseas subsidiaries. Additionally, while the large foreign exchange gains of approximately 1,300 million yen were recorded in the previous period, the period under review has seen a turnaround to foreign exchange losses of approximately 1,000 million yen. As a result, ordinary profit was 2,656 million yen (down 66.6% from the same period of the previous fiscal year), and profit attributable to owners of parent was 1,737 million yen (down 71.3% from the same period of the previous fiscal year).

Below are the results by business segment.

(i) *Ethical Pharmaceuticals Business*

In the domestic market, conditions remained severe due to NHI drug price revisions, the Elective Care Scheme for Long-Listed Products, and the impact of competing products. In overseas markets, sales in the UK, France, and other major markets continued to be favorable. However, sales in the first six months of the current fiscal year declined compared to the first six months of the previous fiscal year. This was due to the impact of a lull in sales in reaction to the large increase in shipments in the fourth quarter of the previous fiscal year in some regions. Additionally, there was a malfunction in the production facilities at a plant to which we outsource the manufacture of Asacol, resulting in an insufficient supply of the product for a certain period. The production facilities have been restored, and the product supply system has already returned to normal.

The Company is striving for early market penetration of Veltassa 8.4g powder for suspension (Single-dose package), a therapeutic agent for hyperkalemia, which was launched in Japan in March 2025.

As a result, net sales in the business amounted to 26,208 million yen (down 8.2% from the same period of the previous fiscal year).

(ii) *Consumer Healthcare Business*

Sales of the mainstay products, the Hepalyse range, the Chondroitin range and the WithOne range of botanical laxative products, increased due in part to the effect of advertising and promotional investments. On the other hand, sales of some products, such as the Prevaline range and the Masdent range, decreased due in part to the impact of competing products.

In addition, new products such as Hepalyse Gastrointestinal Oral Liquid EX, Hepalyse Gastrointestinal Drink and IONA f Night Wrapping Pack were launched during the semi-annual period under review.

As a result, net sales in the business amounted to 13,675 million yen (down 0.9% from the same period of the previous fiscal year).

(iii) *Other*

Net sales in this segment amounted to 76 million yen (up 1.6% from the same period of the previous fiscal year), mainly due to insurance agency business and real estate lease revenue.

(2) Overview of financial position for the semi-annual period under review

(i) Assets, liabilities, and net assets

Total assets at the end of the semi-annual period of the fiscal year ending March 31, 2026 were 158,736 million yen, a decrease of 434 million yen from the end of the previous fiscal year. Current assets increased 479 million yen to 70,009 million yen from the end of the previous fiscal year, and non-current assets decreased 914 million yen to 88,727 million yen from the end of the previous fiscal year. The main changes in current assets included decreases of 939 million yen in cash and deposits and 1,818 million yen in notes and accounts receivable - trade, and an increase of 3,216 million yen in inventories such as merchandise and finished goods. The main change in non-current assets was a decrease of 1,343 million yen in intangible assets.

Total liabilities at the end of the semi-annual period under review were 66,927 million yen, a decrease of 2,447 million yen from the end of the previous fiscal year. Current liabilities decreased 1,027 million yen to 53,421 million yen from the end of the previous fiscal year, and non-current liabilities decreased 1,420 million yen to 13,505 million yen from the end of the previous fiscal year. The main changes in current liabilities were an increase of 1,100 million yen in accounts payable - trade, a decrease of 304 million yen in income taxes payable, a decrease of 446 million yen in provision for bonuses, and a decrease of 1,404 million yen in other of current liabilities, including a decrease in accrued expenses. The main change in non-current liabilities was a decrease of 1,350 million yen in long-term borrowings.

Net assets at the end of the semi-annual period under review were 91,809 million yen, an increase of 2,012 million yen from the end of the previous fiscal year. This was mainly due to profit attributable to owners of parent of 1,737 million yen, payment of 1,057 million yen as dividends declared at the end of the previous period, and an increase of 1,366 million yen in foreign currency translation adjustment.

As a result, the equity ratio at the end of the semi-annual period under review increased by 1.5 percentage points from the end of the previous fiscal year to 57.8%.

(ii) Status of cash flows

Cash and cash equivalents (below, “cash”) at the end of the semi-annual period under review decreased 939 million yen from the end of the previous fiscal year to 22,527 million yen. This was mainly due to net cash used in investing activities of 1,519 million yen and net cash used in financing activities of 3,350 million yen, despite net cash provided by operating activities of 3,390 million yen.

The status of each cash flow and its factors for the semi-annual period under review are as follows.

[Net cash provided by (used in) operating activities]

Net cash provided by operating activities amounted to 3,390 million yen in the semi-annual period under review (down 5,305 million yen from the same period of the previous fiscal year). This was due to factors including profit before income taxes of 2,653 million yen, depreciation of 3,165 million yen, a decrease in trade receivables of 2,326 million yen, an increase in inventories of 2,908 million yen, and income taxes paid of 1,553 million yen.

[Net cash provided by (used in) investing activities]

Net cash used in investing activities totaled 1,519 million yen in the semi-annual period under review (down 373 million yen from the same period of the previous fiscal year). This was mainly due to purchase of property, plant and equipment of 1,272 million yen.

[Net cash provided by (used in) financing activities]

Net cash used in financing activities totaled 3,350 million yen in the semi-annual period under review (up 1,780 million yen from the same period of the previous fiscal year). This was mainly due to a decrease of 419 million yen in short-term borrowings, repayments of long-term borrowings of 1,663 million yen, and dividends paid of 1,055 million yen.

(3) Explanation of consolidated financial forecasts and other forward-looking statements

The full-year consolidated financial forecasts for the fiscal year ending March 31, 2026, which were announced on May 8, 2025, remains unchanged. For more details, please see the Notice regarding Revision of Consolidated Earnings Forecast announced on October 31, 2025.

2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto

(1) Semi-annual consolidated balance sheet

(Thousands of yen)

	As of March 31, 2025	As of September 30, 2025
Assets		
Current assets		
Cash and deposits	23,592,676	22,652,694
Notes and accounts receivable - trade	26,742,165	24,924,065
Merchandise and finished goods	8,592,660	11,062,327
Work in process	2,352,119	2,619,134
Raw materials and supplies	5,489,107	5,968,432
Other	2,892,079	2,861,363
Allowance for doubtful accounts	(131,114)	(78,917)
Total current assets	69,529,694	70,009,099
Non-current assets		
Property, plant and equipment		
Buildings, net	6,437,985	6,207,952
Land	12,658,498	12,657,535
Other, net	7,544,960	7,935,113
Total property, plant and equipment	26,641,444	26,800,601
Intangible assets		
Goodwill	3,621,171	3,294,145
Sales right	27,950,775	26,846,219
Other	8,789,736	8,877,398
Total intangible assets	40,361,683	39,017,763
Investments and other assets		
Investment securities	8,865,571	9,324,328
Retirement benefit asset	13,264,717	13,132,366
Other	541,202	485,213
Allowance for doubtful accounts	(32,717)	(32,593)
Total investments and other assets	22,638,773	22,909,315
Total non-current assets	89,641,902	88,727,679
Total assets	159,171,596	158,736,778
Liabilities		
Current liabilities		
Accounts payable - trade	3,971,467	5,072,292
Short-term borrowings	34,298,379	34,326,199
Income taxes payable	3,773,088	3,468,139
Provision for bonuses	1,623,664	1,176,899
Other	10,782,461	9,378,422
Total current liabilities	54,449,062	53,421,954
Non-current liabilities		
Long-term borrowings	6,865,780	5,515,160
Retirement benefit liability	224,138	261,060
Asset retirement obligations	56,451	56,559
Other	7,779,135	7,672,327
Total non-current liabilities	14,925,506	13,505,108
Total liabilities	69,374,568	66,927,062

(Thousands of yen)

	As of March 31, 2025	As of September 30, 2025
Net assets		
Shareholders’ equity		
Share capital	6,593,398	6,593,398
Capital surplus	11,685,121	9,664,418
Retained earnings	67,207,063	67,886,836
Treasury shares	(18,266,472)	(16,245,860)
Total shareholders’ equity	67,219,110	67,898,793
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,108,422	2,486,994
Foreign currency translation adjustment	16,995,687	18,362,277
Remeasurements of defined benefit plans	3,216,617	2,923,217
Total accumulated other comprehensive income	22,320,727	23,772,488
Non-controlling interests	257,189	138,433
Total net assets	89,797,027	91,809,716
Total liabilities and net assets	159,171,596	158,736,778

(2) Semi-annual consolidated statement of income and semi-annual consolidated statement of comprehensive income

Semi-annual consolidated statement of income

(Thousands of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Net sales	42,422,617	39,960,908
Cost of sales	11,409,066	11,169,685
Gross profit	31,013,551	28,791,222
Selling, general and administrative expenses	24,554,334	25,150,109
Operating profit	6,459,216	3,641,113
Non-operating income		
Interest income	120,528	57,850
Dividend income	225,858	251,217
Foreign exchange gains	1,320,978	–
Other	124,229	131,176
Total non-operating income	1,791,596	440,243
Non-operating expenses		
Interest expenses	232,249	240,107
Foreign exchange losses	–	1,057,838
Other	69,188	127,129
Total non-operating expenses	301,438	1,425,075
Ordinary profit	7,949,373	2,656,282
Extraordinary income		
Gain on sale of non-current assets	2,903	–
Total extraordinary income	2,903	–
Extraordinary losses		
Loss on sale of non-current assets	–	22
Loss on retirement of non-current assets	3,864	2,833
Loss on valuation of investment securities	196,543	–
Total extraordinary losses	200,407	2,855
Profit before income taxes	7,751,869	2,653,426
Income taxes	1,625,522	1,007,002
Profit	6,126,346	1,646,424
Profit (loss) attributable to non-controlling interests	65,065	(91,257)
Profit attributable to owners of parent	6,061,280	1,737,682

Semi-annual consolidated statement of comprehensive income

(Thousands of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Profit	6,126,346	1,646,424
Other comprehensive income		
Valuation difference on available-for-sale securities	(96,198)	378,571
Foreign currency translation adjustment	4,030,007	1,342,145
Remeasurements of defined benefit plans, net of tax	(350,742)	(293,400)
Total other comprehensive income	3,583,067	1,427,316
Comprehensive income	9,709,413	3,073,740
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	9,615,870	3,189,443
Comprehensive income attributable to non-controlling interests	93,542	(115,702)

(3) Semi-annual consolidated statement of cash flows

(Thousands of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash flows from operating activities		
Profit before income taxes	7,751,869	2,653,426
Depreciation	3,386,993	3,165,021
Amortization of goodwill	356,214	354,469
Increase (decrease) in provision for bonuses	(468,042)	(453,338)
Increase (decrease) in retirement benefit liability	32,285	(4,533)
Interest and dividend income	(346,387)	(309,067)
Interest expenses	232,249	240,107
Foreign exchange losses (gains)	(436,150)	446,056
Loss (gain) on valuation of investment securities	196,543	–
Decrease (increase) in trade receivables	(1,667,082)	2,326,671
Decrease (increase) in inventories	(93,461)	(2,908,200)
Increase (decrease) in trade payables	344,542	967,276
Decrease (increase) in other current assets	(66,069)	(485,080)
Increase (decrease) in other current liabilities	110,575	(804,175)
Decrease (increase) in retirement benefit asset	(413,269)	(280,799)
Other, net	18,212	(26,869)
Subtotal	8,939,022	4,880,964
Interest and dividends received	346,377	308,927
Interest paid	(255,680)	(245,992)
Income taxes paid	(334,569)	(1,553,780)
Net cash provided by (used in) operating activities	8,695,150	3,390,119
Cash flows from investing activities		
Payments into time deposits	(430,577)	(125,000)
Proceeds from withdrawal of time deposits	125,000	125,000
Purchase of property, plant and equipment	(732,099)	(1,272,304)
Purchase of intangible assets	(116,966)	(247,292)
Other, net	8,391	(62)
Net cash provided by (used in) investing activities	(1,146,251)	(1,519,658)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(928,550)	(419,000)
Proceeds from long-term borrowings	1,000,000	–
Repayments of long-term borrowings	(4,039,090)	(1,663,500)
Repayments of lease liabilities	(196,698)	(209,923)
Purchase of treasury shares	(626)	(90)
Dividends paid	(965,969)	(1,055,667)
Dividends paid to non-controlling interests	–	(2,717)
Net cash provided by (used in) financing activities	(5,130,935)	(3,350,899)
Effect of exchange rate change on cash and cash equivalents	1,146,622	540,456
Net increase (decrease) in cash and cash equivalents	3,564,586	(939,982)
Cash and cash equivalents at beginning of period	18,604,144	23,467,676
Cash and cash equivalents at end of period	22,168,731	22,527,694

(4) Notes to semi-annual consolidated financial statements

(Notes on significant changes in the scope of consolidation during the period)

During the semi-annual period of the current fiscal year, Kenso-Seiyaku Co., Ltd., the Company's consolidated subsidiary was excluded from the scope of consolidation as it was dissolved in an absorption-type merger with the Company as the surviving company.

(Notes on special accounting methods for preparation of semi-annual consolidated financial statements)

Calculation of tax expenses

Tax expenses were calculated by reasonably estimating the effective tax rate after applying tax effect accounting to the profit before income taxes for the fiscal year that includes the semi-annual period of the current fiscal year and multiplying profit before income taxes by such estimated effective tax rate.

(Notes on segment information, etc.)

[Segment information]

I First six months of the previous fiscal year (from April 1, 2024 to September 30, 2024)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in semi-annual consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	28,544,724	13,802,248	42,346,972	75,645	42,422,617	–	42,422,617
Intersegment sales and transfers	5,457	64	5,521	300,214	305,736	(305,736)	–
Total	28,550,181	13,802,313	42,352,494	375,859	42,728,354	(305,736)	42,422,617
Segment profit	5,830,595	3,121,985	8,952,580	118,312	9,070,892	(2,611,676)	6,459,216

(Notes) 1. "Other" is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (2,611,676) thousand yen is mainly corporate expenses, such as general and administrative expenses that are not allocated to reportable segments.

3. Segment profit is adjusted with operating profit in the semi-annual consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment

Not applicable.

II First six months of the current fiscal year (from April 1, 2025 to September 30, 2025)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in semi-annual consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	26,208,664	13,675,354	39,884,019	76,889	39,960,908	–	39,960,908
Intersegment sales and transfers	–	48	48	239,130	239,178	(239,178)	–
Total	26,208,664	13,675,402	39,884,067	316,019	40,200,087	(239,178)	39,960,908
Segment profit	3,422,072	3,170,897	6,592,969	88,531	6,681,501	(3,040,387)	3,641,113

(Notes) 1. "Other" is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (3,040,387) thousand yen is mainly corporate expenses, such as general and administrative expenses that are not allocated to reportable segments.

3. Segment profit is adjusted with operating profit in the semi-annual consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment

Not applicable.

(Notes on significant changes in the amount of shareholders' equity)

Not applicable.

(Notes on premise of a going concern)

Not applicable.

(Notes on significant subsequent events)

Cancellation of treasury shares

At a meeting of the Board of Directors held on November 5, 2025, the Company resolved to cancel its treasury shares held by the Company in accordance with the provisions of Article 178 of the Companies Act.

For more details, please see the Notice regarding Cancellation of Treasury Shares announced on November 5, 2025.

3. Supplemental Information

(1) Sales of major products and merchandise Consolidated

(Thousands of yen)

	First six months of the previous fiscal year (from April 1, 2024 to September 30, 2024)	First six months of the current fiscal year (from April 1, 2025 to September 30, 2025)	Percentage change (%)
1. Ethical Pharmaceuticals Business	28,544,724	26,208,664	(8.2)
DIFICLIR	9,889,515	9,852,150	(0.4)
Asacol	11,254,403	9,843,956	(12.5)
Entocort	2,630,933	1,850,690	(29.7)
Acofide	1,526,589	1,568,239	2.7
Other	3,243,282	3,093,627	(4.6)
2. Consumer Healthcare Business	13,802,248	13,675,354	(0.9)
Hepalyse range	5,877,864	6,427,756	9.4
Chondroitin range	2,825,598	2,897,235	2.5
WithOne range	722,551	737,757	2.1
Other	4,376,234	3,612,604	(17.4)
3. Other Business	75,645	76,889	1.6
Total	42,422,617	39,960,908	(5.8)

(2) Status of pipeline of new drugs

I. Domestic

As of November 5, 2025

Stage	Development Code/Generic Name	Development	Indications	Classification	Origin
Phase III	Z-338/Acotiamide	Zeria	Pediatric functional dyspepsia	Upper gastrointestinal motility modulator	Original
Phase II	ZG-802/Acotiamide	Zeria	Underactive bladder	Lower urinary tract function modulator	Original
Phase II (Specified Clinical Trial)	Z-100	Nonprofit Organization, North East Japan Study Group	Non-small cell lung cancer	Immunomodulator	Original

II. Overseas

Stage	Development Code/Generic Name	Development	Indications	Classification	Origin
NDA approved (Nicaragua)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
NDA filed (Vietnam)	Z-338/Acotiamide	Pharmaceutical Joint Stock Company of February 3rd	Functional dyspepsia	Upper gastrointestinal motility modulator	Original
NDA filed (Colombia, Costa Rica, Panama)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
Phase III (Europe, United States, Canada)	Z-338/Acotiamide	Agastra-Lab s.r.l.	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)

Launched

Launch Date	Development Code/Generic Name	Development	Indications	Classification	Origin
November 2024 (Peru)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
March 2025 (Japan)	ZG-801/Patiromer Sorbitex Calcium (Brand name: Veltassa 8.4g powder for suspension (Single-dose package))	Zeria	Hyperkalemia	Potassium binder	In-licensed